Nanomedicine in the diagnosis and therapy of neurodegenerative disorders

A. V. Kabanov, Howard Eliot Gendelman

Research output: Contribution to journalReview article

164 Citations (Scopus)

Abstract

Neurodegenerative and infectious disorders including Alzheimer's and Parkinson's diseases, amyotrophic lateral sclerosis, and stroke are rapidly increasing as population's age. Alzheimer's disease alone currently affects 4.5 million Americans, and more than $100 billion is spent per year on medical and institutional care for affected people. Such numbers will double in the ensuing decades. Currently disease diagnosis for all disorders is made, in large measure, on clinical grounds as laboratory and neuroimaging tests confirm what is seen by more routine examination. Achieving early diagnosis would enable improved disease outcomes. Drugs, vaccines or regenerative proteins present "real" possibilities for positively affecting disease outcomes, but are limited in that their entry into the brain is commonly restricted across the blood-brain barrier. This review highlights how these obstacles can be overcome by polymer science and nanotechnology. Such approaches may improve diagnostic and therapeutic outcomes. New developments in polymer science coupled with cell-based delivery strategies support the notion that diseases that now have limited therapeutic options can show improved outcomes by advances in nanomedicine.

Original languageEnglish (US)
Pages (from-to)1054-1082
Number of pages29
JournalProgress in Polymer Science (Oxford)
Volume32
Issue number8-9
DOIs
StatePublished - Aug 1 2007

Fingerprint

Medical nanotechnology
therapy
disorders
Polymers
Parkinson disease
blood-brain barrier
Neuroimaging
vaccines
Vaccines
polymers
nanotechnology
strokes
Nanotechnology
entry
brain
Brain
delivery
drugs
examination
proteins

Keywords

  • Bioimaging
  • Blood-brain barrier
  • Magnetic resonance spectroscopy
  • Nanomedicine
  • Neurodegenerative disorders
  • Polymer chemistry

ASJC Scopus subject areas

  • Ceramics and Composites
  • Surfaces and Interfaces
  • Polymers and Plastics
  • Organic Chemistry
  • Materials Chemistry

Cite this

Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. / Kabanov, A. V.; Gendelman, Howard Eliot.

In: Progress in Polymer Science (Oxford), Vol. 32, No. 8-9, 01.08.2007, p. 1054-1082.

Research output: Contribution to journalReview article

@article{32b5bed8451242b7b6a8023ebdd63fbd,
title = "Nanomedicine in the diagnosis and therapy of neurodegenerative disorders",
abstract = "Neurodegenerative and infectious disorders including Alzheimer's and Parkinson's diseases, amyotrophic lateral sclerosis, and stroke are rapidly increasing as population's age. Alzheimer's disease alone currently affects 4.5 million Americans, and more than $100 billion is spent per year on medical and institutional care for affected people. Such numbers will double in the ensuing decades. Currently disease diagnosis for all disorders is made, in large measure, on clinical grounds as laboratory and neuroimaging tests confirm what is seen by more routine examination. Achieving early diagnosis would enable improved disease outcomes. Drugs, vaccines or regenerative proteins present {"}real{"} possibilities for positively affecting disease outcomes, but are limited in that their entry into the brain is commonly restricted across the blood-brain barrier. This review highlights how these obstacles can be overcome by polymer science and nanotechnology. Such approaches may improve diagnostic and therapeutic outcomes. New developments in polymer science coupled with cell-based delivery strategies support the notion that diseases that now have limited therapeutic options can show improved outcomes by advances in nanomedicine.",
keywords = "Bioimaging, Blood-brain barrier, Magnetic resonance spectroscopy, Nanomedicine, Neurodegenerative disorders, Polymer chemistry",
author = "Kabanov, {A. V.} and Gendelman, {Howard Eliot}",
year = "2007",
month = "8",
day = "1",
doi = "10.1016/j.progpolymsci.2007.05.014",
language = "English (US)",
volume = "32",
pages = "1054--1082",
journal = "Progress in Polymer Science",
issn = "0079-6700",
publisher = "Elsevier Limited",
number = "8-9",

}

TY - JOUR

T1 - Nanomedicine in the diagnosis and therapy of neurodegenerative disorders

AU - Kabanov, A. V.

AU - Gendelman, Howard Eliot

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Neurodegenerative and infectious disorders including Alzheimer's and Parkinson's diseases, amyotrophic lateral sclerosis, and stroke are rapidly increasing as population's age. Alzheimer's disease alone currently affects 4.5 million Americans, and more than $100 billion is spent per year on medical and institutional care for affected people. Such numbers will double in the ensuing decades. Currently disease diagnosis for all disorders is made, in large measure, on clinical grounds as laboratory and neuroimaging tests confirm what is seen by more routine examination. Achieving early diagnosis would enable improved disease outcomes. Drugs, vaccines or regenerative proteins present "real" possibilities for positively affecting disease outcomes, but are limited in that their entry into the brain is commonly restricted across the blood-brain barrier. This review highlights how these obstacles can be overcome by polymer science and nanotechnology. Such approaches may improve diagnostic and therapeutic outcomes. New developments in polymer science coupled with cell-based delivery strategies support the notion that diseases that now have limited therapeutic options can show improved outcomes by advances in nanomedicine.

AB - Neurodegenerative and infectious disorders including Alzheimer's and Parkinson's diseases, amyotrophic lateral sclerosis, and stroke are rapidly increasing as population's age. Alzheimer's disease alone currently affects 4.5 million Americans, and more than $100 billion is spent per year on medical and institutional care for affected people. Such numbers will double in the ensuing decades. Currently disease diagnosis for all disorders is made, in large measure, on clinical grounds as laboratory and neuroimaging tests confirm what is seen by more routine examination. Achieving early diagnosis would enable improved disease outcomes. Drugs, vaccines or regenerative proteins present "real" possibilities for positively affecting disease outcomes, but are limited in that their entry into the brain is commonly restricted across the blood-brain barrier. This review highlights how these obstacles can be overcome by polymer science and nanotechnology. Such approaches may improve diagnostic and therapeutic outcomes. New developments in polymer science coupled with cell-based delivery strategies support the notion that diseases that now have limited therapeutic options can show improved outcomes by advances in nanomedicine.

KW - Bioimaging

KW - Blood-brain barrier

KW - Magnetic resonance spectroscopy

KW - Nanomedicine

KW - Neurodegenerative disorders

KW - Polymer chemistry

UR - http://www.scopus.com/inward/record.url?scp=34547601983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547601983&partnerID=8YFLogxK

U2 - 10.1016/j.progpolymsci.2007.05.014

DO - 10.1016/j.progpolymsci.2007.05.014

M3 - Review article

C2 - 20234846

AN - SCOPUS:34547601983

VL - 32

SP - 1054

EP - 1082

JO - Progress in Polymer Science

JF - Progress in Polymer Science

SN - 0079-6700

IS - 8-9

ER -